• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » August 2004 – The CenterWatch Monthly : Volume 11, Issue 8, August 2004
August 2004 – The CenterWatch Monthly : Volume 11, Issue 8, August 2004

August 2004 – The CenterWatch Monthly : Volume 11, Issue 8, August 2004

$79.00

Product Details

Phase I Spending Sizzles

While INDs remain flat, the phase I market is hot. Sponsors are spending more than ever in phase I on larger and more complex trials, and CROs are taking advantage of the trend toward more outsourcing of phase I. Owners of phase I units have also found it to be a seller’s market. In the short- to mid-term, a capacity crunch could emerge. The phase I market is expected to grow about 16% in 2004 to $4.1 billion, fueled by sponsors’ emphasis on becoming more efficient developing drugs by killing poor drug candidates before they enter more expensive phase II and III trials.

Foundations Venture into Clinical Research

Disease-focused foundations are motivated to become active players in the clinical research process by aiding patient recruitment and funding academic research; they are beginning to fund commercial clinical trials.

Canceropole Lyon Rhone-Alpes, a New Regional Network Fights Cancer

The decision to form Cancerpole Lyon Rhone-Alpes, a non-profit regional network comprising 15 public institutions and 35 private companies involved in cancer research and development was a followed a year of study.

Eye On: Cystic Fibrosis

Cystic fibrosis affects more than 30,000 Americans. CenterWatch has identified a pipeline of 17 drugs in development for cystic fibrosis.

  • Month in Review
  • In the Pipeline
  • Opportunities Underway
  • TrialWatch
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing